T. Miller

发表

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

L. Staudt, A. Rosenwald, J. Powell, 2002, The New England journal of medicine.

Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma

L. Rimsza, T. Grogan, T. Miller, 2007, Laboratory Investigation.

Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma

L. Staudt, A. Rosenwald, Xin Yu, 2003, The Journal of experimental medicine.

Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.

L. Staudt, A. Rosenwald, J. Powell, 2004, The New England journal of medicine.

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.

L. Staudt, A. Rosenwald, J. Powell, 2003, Cancer cell.

Stromal gene signatures in large-B-cell lymphomas.

L. Staudt, W. C. Chan, A. Rosenwald, 2008, The New England journal of medicine.

Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival.

Adrian Wiestner, Hui Liu, Kazutaka Nakayama, 2007, Blood.

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

P. Meltzer, T. Grogan, T. Miller, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib

T. Miller, M. Soengas, J. Esteban, 2006, Journal of Biological Chemistry.

Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.

J. Cerhan, A. Zelenetz, J. Friedberg, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T‐cell non‐Hodgkin lymphoma

R. Fisher, T. Miller, M. Leblanc, 2013, Cancer.

Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

T. Miller, T. Kipps, J. Gabrilove, 2016, Haematologica.

The role of P-glycoprotein in drug-resistant hematologic malignancies.

T. Grogan, T. Miller, W. Dalton, 1991, Cancer treatment and research.

Utility of fine-needle aspiration as a diagnostic technique in lymphoma.

T. Grogan, T. Miller, S. Hehn, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study.

R. Fisher, T. Grogan, T. Miller, 2001, Journal of Clinical Oncology.

Localized large cell lymphoma: is there any need for radiation therapy?

T. Miller, D. Persky, 2009, Current opinion in oncology.

A phase I/II trial of paclitaxel for non‐Hodgkin's lymphoma followed by paclitaxel plus quinine in drug‐resistant disease

T. Miller, W. Dalton, R. Dorr, 1998, Anti-cancer drugs.

Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group Study.

T. Miller, S. Balcerzak, H. Eyre, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501.

R. Fisher, T. Grogan, T. Miller, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination o f F ludarabine a nd M itoxantrone i n U ntreated Stages I II a nd I V L ow-Grade L ymphoma: S 9501

R. Fisher, T. Grogan, T. Miller, 2003 .

Treatment of diffuse large-cell lymphoma: a summary of outcome for patients treated by Southwest Oncology Group.

T. Miller, S. Dahlberg, 1993, Cancer treatment and research.

Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy.

J. Connors, T. Miller, Stephen E. Jones, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.

R. Fisher, T. Grogan, T. Miller, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.

R. Fisher, D. Longo, T. Miller, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

The use of chemotherapy for localized large cell lymphoma. Results from the University of Arizona

T. Miller, S. Jones, 1985 .

Is there a role for radiotherapy in localized diffuse lymphomas?

T. Miller, Stephen E. Jones, S. Jones, 2004, Cancer Chemotherapy and Pharmacology.

Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).

R. Fisher, T. Grogan, T. Miller, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 trial of CHOP chemotherapy followed by tositumomab / iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma : Southwest Oncology Group Protocol S 9911

R. Fisher, T. Miller, M. Leblanc, 2003 .

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

T M Grogan, T P Miller, R. Fisher, 1993, The New England journal of medicine.

Combined chemotherapy plus radiotherapy for treatment of earlystage intermediate- and high-grade non-Hodgkin’s lymphoma

T. Miller, J. Briggs, 2000, Current oncology reports.

The phenomenon of multidrug resistance in non-Hodgkin’s lymphoma

T. Grogan, T. Miller, W. Dalton, 1997 .

m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial.

R. Fisher, T. Miller, C. Coltman, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.

R. Advani, R. Gascoyne, L. Gordon, 2013, Blood.

Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.

J. Friedberg, J. Winter, L. Rimsza, 2013, The New England journal of medicine.

P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.

T. Grogan, T. Miller, W. Dalton, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease.

T. Miller, R. Silver, R. Wheeler, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vincristine, and mitomycin C (FOMi).

T. Miller, R. Livingston, L. J. McMahon, 1980, Cancer treatment reports.

Immunotyping malignant lymphomas. A boon to diagnosis.

T. Grogan, T. Miller, C. Spier, 1986, Cleveland Clinic quarterly.

Radiation therapy salvage of Hodgkin's disease following chemotherapy failure.

T. Miller, M. Baier, J. Cassady, 1993, International journal of radiation oncology, biology, physics.

Salvage therapy of advanced Hodgkin's disease. Critical appraisal of curative potential.

T. Miller, S. Lippman, A. Buzaid, 1987, The American journal of medicine.

Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma

T. Miller, H. Garewal, Stephen E. Jones, 2004, Investigational New Drugs.

Mistaken clinical and pathologic diagnoses of Hodgkin's disease: a Southwest oncology group study.

T. Miller, S. Jones, G. Byrne, 1982, Cancer treatment reports.

Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group Study S0108

L. Rimsza, R. Fisher, T. Miller, 2005 .

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.

L. Gordon, M. Czuczman, J. Friedberg, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.

J. Vose, L. Gordon, M. Czuczman, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma

R. Fisher, T. Miller, Ann M Manziello, 2012, Clinical Cancer Research.

Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.

L. Rimsza, T. Miller, W. Qi, 2011, Biochemical pharmacology.

The limits of limited stage lymphoma.

T. Miller, 2004, Journal of Clinical Oncology.

Molecular diagnosis of Burkitt's lymphoma.

Richard Simon, Kai Fu, Jan Delabie, 2006, The New England journal of medicine.

Radiation therapy salvage of Hodgkin's disease following chemotherapy failure.

T. Miller, S. Lippman, J. Cassady, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer Therapy : Preclinical Aurora A Inhibitor ( MLN 8237 ) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma

R. Fisher, T. Miller, Ann M Manziello, 2012 .

Peripheral T-cell lymphoma: aggressive disease with heterogeneous immunotypes.

T. Grogan, T. Miller, M. Hicks, 1985, American journal of clinical pathology.

Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.

R. Fisher, T. Miller, C. Coltman, 1988, Seminars in hematology.

Mood alterations in patients treated with chlorambucil.

T. Miller, R. Dorr, S. Hehn, 2003, Clinical lymphoma.

Cyclophosphamide, vincristine, cisplatin, VP-16 and radiation therapy in extensive small-cell lung cancer

T. Miller, R. Livingston, C. Higano, 1989, Cancer Chemotherapy and Pharmacology.

Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL).

J. Friedberg, J. Winter, R. Fisher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration.

T. Miller, W. Dalton, C. Appleton, 1991, Journal of the National Cancer Institute.

Reply to M.C. Chamberlain

J. Friedberg, R. Fisher, T. Miller, 2009 .

A Multi Center Trial of hyperCVAD+Rituxan in Patients with Newly Diagnosed Mantle Cell Lymphoma.

R. Fisher, T. Miller, M. Leblanc, 2007 .

Extensive non-small cell lung cancer treated with mitomycin, cisplatin, and vindesine (MiPE): a Southwest Oncology Group Study.

T. Miller, S. Rodney, R. Vance, 1986, Cancer treatment reports.

Post-transplantation T cell lymphoblastic lymphoma.

T. Grogan, T. Miller, S. Lippman, 1987, The American journal of medicine.

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.

J. Cerhan, A. Zelenetz, J. Friedberg, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy of advanced non-small cell lung cancer

T. Miller, B. Takasugi, B. J. Takasugi, 2004, Investigational New Drugs.

Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.

R. Fisher, T. Miller, C. Coltman, 1987, Seminars in hematology.

Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.

R. Fisher, T. Miller, H. Eyre, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B‐cell lymphomas

T. Miller, W. Qi, L. Cooke, 2012, International journal of cancer.

Evaluation of anticancer drug schedule dependency using an in vitro human tumor clonogenic assay

D. Alberts, T. Miller, S. Salmon, 1984, Cancer Chemotherapy and Pharmacology.

A phase II study of PXD101 (belinostat) in relapsed and refractory aggressive B-cell lymphomas (rel/ref ABCL): SWOG S0520.

L. Rimsza, R. Fisher, T. Miller, 2012 .

Reversal of multidrug resistance in hematologic malignancies with chemosensitizers: laboratory and clinical studies

T. Grogan, T. Miller, W. Dalton, 1994 .

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.

R. Fisher, T. Miller, M. Leblanc, 2003, Blood.

New biologic markers in non-Hodgkin's lymphomas.

T. Grogan, T. Miller, 1991, Hematology/oncology clinics of North America.

Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma.

T. Grogan, T. Miller, Y. Frutiger, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Loss of B 7 . 2 ( CD 86 ) and Intracellular Adhesion Molecule 1 ( CD 54 ) Expression Is Associated with Decreased Tumor-infiltrating T Lymphocytes in Diffuse B-cell Large-cell Lymphoma 1

Cynthia S. Johnson, T. Grogan, T. Miller, 2000 .

What should be the morphologic criteria for the subdivision of follicular lymphomas?

Bharat, B. Nathwani, T. Miller, 1986, Blood.

Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.

L. Rimsza, R. Fisher, T. Miller, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL).

L. Staudt, A. Rosenwald, W. Chan, 2006 .

The aberrancy of immunophenotype and immunoglobulin status as indicators of prognosis in B cell diffuse large cell lymphoma.

T. Grogan, T. Miller, S. Lippman, 1988, The American journal of pathology.

Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder

Alan M. Miller, L. Gordon, R. Fisher, 2008, Transplantation.

Management of intermediate-grade lymphomas.

T. Miller, 1998, Oncology.

Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial.

Ellen, Tubbs, B. Nathwani, 1994, Blood.

Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures

T. Grogan, T. Miller, C. Riley, 2005, Molecular Cancer Therapeutics.

The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype.

T. Grogan, T. Miller, S. Lippman, 1988, Blood.

Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.

S. Lowe, T. Miller, M. Soengas, 2005, Cancer research.

HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma.

T. Grogan, T. Miller, S. Lippman, 1988, The Journal of clinical investigation.

Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment.

T. Miller, W. Qi, A. Agarwal, 2013, Leukemia research.

The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features.

R. Fisher, T. Grogan, T. Miller, 2001, Blood.

Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67

T. Grogan, T. Miller, S. Lippman, 1988 .

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.

L. Staudt, A. Rosenwald, W. Chan, 2004, Blood.

Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

T. Miller, T. Kipps, A. Roberts, 2013 .

A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis.

Robin A Roberts, Margaret M Briehl, L. Rimsza, 2005, Blood.

Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease.

R. Fisher, T. Grogan, T. Miller, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial chemotherapy for clinically localized lymphomas of unfavorable histology.

T. Miller, Stephen E. Jones, S. Jones, 1983, Blood.

A Southwest Oncology Group perspective on the Revised European-American Lymphoma classification.

R. Fisher, T. Grogan, T. Miller, 1997, Hematology/oncology clinics of North America.

NCAM (CD56)-positive malignant lymphoma.

T. Grogan, T. Miller, W. Kern, 1993, Leukemia & lymphoma.

A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study.

B. Nathwani, R. Fisher, T. Grogan, 1995, Blood.

The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496

R. Advani, R. Gascoyne, L. Gordon, 2013, British journal of haematology.

A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108

L. Rimsza, R. Fisher, T. Miller, 2009, Leukemia & lymphoma.

Gene Expression Profile of Serial Samples of Transformed B-Cell Lymphomas

T. Grogan, T. Miller, W. Wachsman, 2003, Laboratory Investigation.

Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement.

T. Grogan, T. Miller, W. Kern, 1992, Blood.

Morphological subclassification of follicular lymphoma: variability of diagnoses among hematopathologists, a collaborative study between the Repository Center and Pathology Panel for Lymphoma Clinical Studies.

C C Whitcomb, B N Nathwani, R B Mann, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.

B. Nathwani, R. Fisher, T. Miller, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.

J. Friedberg, R. Fisher, T. Miller, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer.

T. Grogan, T. Miller, W. Dalton, 1991, Blood.

A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab

M. Kaminski, M. Czuczman, J. Friedberg, 2013, Clinical Cancer Research.

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.

M. Kaminski, M. Czuczman, J. Friedberg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520

Sonali M. Smith, J. Friedberg, L. Rimsza, 2016, Leukemia & lymphoma.

comments) rare variant with a propensity for unusual sites of involvement (see Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a

T. Grogan, T. Miller, W. Kern, 2011 .

Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.

R. Fisher, T. Grogan, T. Miller, 1998, The New England journal of medicine.

Follicular lymphomas: do histologic subtypes predict outcome?

R. Fisher, T. Grogan, T. Miller, 1997, Hematology/oncology clinics of North America.

Low-Dose Involved Field Radiation after Chemotherapy in Advanced Hodgkin Disease: A Southwest Oncology Group Randomized Study

T. Miller, C. Coltman, C. Mansfield, 1994, Annals of Internal Medicine.

Diffuse small cleaved-cell lymphoma: a heterogeneous disease with distinct immunobiologic subsets.

T. Grogan, T. Miller, J. Rybski, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group study.

R. Fisher, T. Miller, S. Salmon, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: a Southwest Oncology Group study.

R. Fisher, T. Miller, S. Balcerzak, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class II (HLA-DR, DP, DQ) and Class I (HLA-A, B, C) Phenotype.

T. Grogan, T. Miller, S. Lippman, 1991, Leukemia & lymphoma.

Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study.

J. Crowley, T. Miller, R. Livingston, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

What should be the morphologic criteria for the subdivision of follicular lymphomas

B. Nathwani, T. Miller, M. Barcos, 1986 .

survival in mantle cell lymphoma mRNAs that are associated with increased proliferation rate and shorter Point mutations and genomic deletions in Cyclin D1 create stable truncated

L. Staudt, A. Rosenwald, W. Chan, 2013 .

Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.

L. Staudt, A. Rosenwald, W. Chan, 2005, Blood.

Chapter 4 Molecular Diagnosis of Burkitt lymphoma

Armitage, L. Staudt, A. Rosenwald, 2019 .

Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.

Sonali M. Smith, J. Friedberg, J. Leonard, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diffuse aggressive lymphoma.

R. Fisher, T. Miller, O. O’Connor, 2004, Hematology. American Society of Hematology. Education Program.

New treatment options have changed the survival of patients with follicular lymphoma.

R. Fisher, T. Miller, M. Leblanc, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues

L. Staudt, A. Rosenwald, W. Chan, 2011, Clinical Cancer Research.

Paraffin-Embedded Tissues Nuclease Protection Assay on Formalin-Fixed , into Germinal Center and Activated B-Cell Subtypes Using a Accurate Classification of Diffuse Large B-Cell Lymphoma

L. Staudt, A. Rosenwald, W. Chan, 2011 .

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.

A. Rosenwald, R. Gascoyne, L. Sehn, 2008, Blood.

Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival.

L. Staudt, A. Rosenwald, W. Chan, 2006, Blood.

Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67.

T. Grogan, T. Miller, S. Lippman, 1988, Blood.

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.

J. Cerhan, A. Zelenetz, J. Friedberg, 2013 .

Comparison of lymphangiography and computed tomography scanning in evaluating abdominal disease in stages III and IV Hodgkin's disease: A southwest oncology group study

T. Miller, C. Mansfield, F. Morrison, 1990, Cancer.

R‐CHOP with iodine‐131 tositumomab consolidation for advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0433

A. Nademanee, M. Kaminski, J. Friedberg, 2014, British journal of haematology.

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

T. Miller, T. Kipps, J. Gabrilove, 2013 .

Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience.

T. Miller, H. Wilson, S. Jones, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.

L. Rimsza, R. Fisher, T. Miller, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

External Beam Radiation Therapy in the Treatment of Patients With Extranodal Stage IA Non-Hodgkin’s Lymphoma

T. Miller, J. Oleson, J. Briggs, 2002, American Journal of Clinical Oncology.

Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer

T. Miller, S. Green, H. Hynes, 2004, Investigational New Drugs.

Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course.

T. Grogan, T. Miller, S. Lippman, 1990, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma.

T. Grogan, T. Miller, S. Lippman, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

L. Rimsza, R. Fisher, T. Miller, 2012, Haematologica.

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma.

Derick R. Peterson, J. Friedberg, L. Rimsza, 2014, Blood.

Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

T. Miller, T. Kipps, A. Roberts, 2013 .

Diffuse aggressive histologies of non-hodgkin lymphoma: treatment and biology of limited disease.

L. Rimsza, T. Miller, C. Spier, 2006, Seminars in hematology.

Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.

R. Fisher, T. Miller, M. Leblanc, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine.

T. Miller, H. Garewal, S. Jones, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of small cell lung cancer with VP-16, vincristine, doxorubicin (Adriamycin), cyclophosphamide (EVAC), and high-dose chest radiotherapy.

T. Miller, G. Goodman, M. Manning, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation consolidation following MOP-BAP for stages III & IV Hodgkin's disease, A randomized Southwest Oncology study

R. Fisher, T. Miller, C. Coltman, 1991 .

Genetic polymorphisms in oxidative stress‐related genes are associated with outcomes following treatment for aggressive B‐cell non‐Hodgkin lymphoma

J. Cerhan, L. Rimsza, R. Fisher, 2014, American journal of hematology.

Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vindesine, and mitomycin (FEMi): a Southwest Oncology Group Study.

T. Miller, J. Weick, P. Grozea, 1982, Cancer treatment reports.

Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors.

T. Miller, S. Jones, A. Chester, 1980, Cancer treatment reports.

Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence.

T. Grogan, T. Miller, A. List, 1993, Leukemia.

Second-line therapy in follicular lymphoma in the United States: Report of NLCS observational study.

J. Cerhan, A. Zelenetz, J. Friedberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515

L. Rimsza, R. Fisher, T. Miller, 2010 .

Racial differences in presentation and management of follicular non‐Hodgkin lymphoma in the United States

J. Cerhan, J. Friedberg, C. Flowers, 2012, Cancer.

Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.

R. Fisher, T. Miller, J. Forman, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene expression distinguishes Burkitt lymphoma from other aggressive lymphomas and identifies patients who are highly curable with intensive chemotherapeutic regimens.

L. Staudt, A. Rosenwald, J. Powell, 2005 .

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.

J. Friedberg, R. Fisher, T. Miller, 2015, Blood.

Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2

D. Mount, R. Fisher, T. Miller, 2014, PloS one.

Effect of Adding Rituximab to Three Cycles of CHOP Plus Invoved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014).

R. Fisher, T. Miller, M. Leblanc, 2004 .

Malignant lymphomas in patients with human immunodeficiency virus infection.

T. Miller, E. Hersh, 1988, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma

M. Kaminski, M. Czuczman, J. Friedberg, 2011 .

Heart of Lymphoma: Primary Mediastinal Large B-Cell Lymphoma with Endomyocardial Involvement

T. Miller, M. Bookman, H. Babiker, 2013, Case reports in oncological medicine.

Chest irradiation (RT) vs. chest RT + chemotherapy ± prophylactic brain RT in localized non small cell lung cancer: A southwest oncology group randomized study

J. Crowley, T. Miller, J. Mira, 1990 .

Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung. A Southwest Oncology Group Study.

T. Miller, C. Coltman, R. Livingston, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lennert's lymphoma: A clinicopathologic study with emphasis on phenotype and its relationship to survival

T. Grogan, T. Miller, S. Lippman, 1988, Cancer.

A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.

L. Rimsza, R. Fisher, T. Miller, 2012, Blood.

New Treatment Options Have Changed the Natural History of Follicular Lymphoma.

R. Fisher, T. Miller, M. Leblanc, 2004 .

Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313)

J. Friedberg, R. Fisher, T. Miller, 2008 .

Updated Results from a Phase II Study of Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory, Follicular NHL.

L. Gordon, M. Czuczman, J. Friedberg, 2005 .

Examination of the Follicular Lymphoma International Prognostic Index (FLIPI) in the National LymphoCare Study (NLCS): A U.S. patient cohort treated predominantly in community practices.

J. Cerhan, A. Zelenetz, J. Friedberg, 2011, Journal of Clinical Oncology.

Pseudonodular T cell lymphoblastic lymphoma.

T. Grogan, T. Miller, J. E. Schwartz, 1984, The American journal of medicine.

Phase II trial of bisantrene in non-small cell lung cancer

D. Alberts, T. Miller, B. Greenberg, 2004, Investigational New Drugs.

Lymphdx: A Custom Microarray for Molecular Diagnosis and Prognosis in Non-Hodgkin Lymphoma.

L. Staudt, A. Rosenwald, J. Powell, 2004 .

Fc Gamma Receptor 3a Genotype Predicts Overall Survival for Follicular Lymphoma Patients Treated On Southwest Oncology Group Trials with Combined Monoclonal Antibody Plus Chemotherapy but Not Chemotherapy Alone.

L. Rimsza, R. Fisher, T. Miller, 2009 .

Mitotic counts in follicular lymphomas.

B. Nathwani, T. Miller, R. Turner, 1987, Human pathology.

R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433

J. Friedberg, R. Fisher, T. Miller, 2010 .

Directed indices for exploring gene expression data

Michael LeBlanc, Charles L. Kooperberg, Thomas M. Grogan, 2003, Bioinform..

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Meland, L. Staudt, A. Rosenwald, 2002, The New England journal of medicine.

Southwest Oncology Group clinical trials of chemosensitizers in non-Hodgkinʼs lymphomas: 166

R. Fisher, T. Grogan, T. Miller, 1994 .

Phase II trial of 5-FU, vincristine, and mitomycin (FOMi) in metastatic bronchioloalveolar cell lung cancer: a Southwest Oncology Group Study.

T. Miller, R. Livingston, 1985, Cancer treatment reports.

A phase II study of bisantrene in malignant lymphomas

T. Miller, Stephen E. Jones, J. Cowan, 2004, Cancer Chemotherapy and Pharmacology.

Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas

D. Alberts, T. Miller, Stephen E. Jones, 2004, Investigational New Drugs.

Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder

L. Gordon, R. Fisher, T. Grogan, 2008, Transplantation.

U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881).

J. Friedberg, C. Flowers, R. Fisher, 2014 .

Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.

J. Cerhan, A. Zelenetz, J. Friedberg, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis.

L. Rimsza, T. Grogan, T. Miller, 2005, Blood.

Chemohormonal therapy for advanced breast cancer with tamoxifen, adriamycin, and cyclophosphamide (TAC)

T. Miller, Stephen E. Jones, T. Moon, 1985, Cancer.

Fcγ Receptor Polymorphisms Do Not Influence Progression Free Survival (PFS) of Follicular NHL Pateints Treated with Chop Followed by Rituximab (SWOG 9800).

R. Fisher, J. Radich, T. Grogan, 2004 .

A Southwest Oncology Group phase II evaluation of fluderabine monophosphate in sarcoma

T. Miller, S. Dakhil, S. Balcerzak, 2004, Investigational New Drugs.

L. Rimsza, R. Fisher, T. Miller, 2012, Blood.